title: [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
abstract: We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.
authors.affiliation: Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Takuya
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Akihito
authors.initials: A
authors.lastname: Fujimi
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Ryoya
authors.initials: R
authors.lastname: Seki
authors.forename: Ikuta
authors.initials: I
authors.lastname: Tanaka
authors.forename: Naofumi
authors.initials: N
authors.lastname: Takemoto
authors.forename: Takehide
authors.initials: T
authors.lastname: Akiyama
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Takeshi
authors.initials: T
authors.lastname: Terui
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Kogawa
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
authors.forename: Toshiro
authors.initials: T
authors.lastname: Kura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Maeda
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate